Human skin permeation of 3-O-alkyl carbamate prodrugs of naltrexone

Journal of Pharmaceutical Sciences

Volumn 98, Issue 8, 2009, Pages 2611-2625

  Vaddi, Haranath K ^a,b   Banks, Stan L ^a,c   Chen, Jianhong ^a,d   Hammell, Dana C ^a   Crooks, Peter A ^a   Stinchcomb, Audra L ^a  

^a University of Kentucky   (United States)

^b Novartis   (United States)

^c AllTranz Inc   (United States)

^d CLEMSON UNIVERSITY   (United States)

Author keywords

Bioconversion; Carbamates; Cross sectional area; Naltrexone; Prodrugs; Skin permeation

Indexed keywords

BUFFER; BUTYL NALTREXONE 3 O CARBAMATE; CARBAMIC ACID DERIVATIVE; ETHYL NALTREXONE 3 O CARBAMATE; MINERAL OIL; N,N DIETHYL NALTREXONE 3 O CARBAMATE; N,N DIISOPROPYL NALTREXONE 3 O CARBAMATE; N,N DIMETHYL NALTREXONE 3 O CARBAMATE; NALTREXONE; PENTYL NALTREXONE 3 O CARBAMATE; PRODRUG; PROPYL NALTREXONE 3 O CARBAMATE; UNCLASSIFIED DRUG;

ARTICLE; BIOTRANSFORMATION; CONTROLLED STUDY; DRUG DISPOSITION; DRUG HYDROLYSIS; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; HUMAN; HUMAN TISSUE; MELTING POINT; PARTITION COEFFICIENT; PHYSICAL CHEMISTRY; SKIN PERMEABILITY; STRATUM CORNEUM;

EID: 68249115720     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21594     Document Type: Article

References (62)

1. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. 1992. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 49:876-880.
2. Terenius L. 1998. Rational treatment of addiction. Curr Opin Chem Biol 2:541-547.
3. 1996. PDR generics. 2nd edition. New Jersey: Medical Economics. pp. 2229-2233.
4. Rothenberg JL, Sullivan MA, Church SH, Seracini A, Collins E, Kleber HD, Nunes EV. 2002. Behavioral naltrexone therapy: An integrated treatment for opiate dependence. J Subst Abuse Treat 23:351-360. (Pubitemid 35477814)
5. Volpicelli JR, Rhines KC, Rhines JS, Volpicelli LA, Alterman AI, O'Brien CP. 1997. Naltrexone and alcohol dependence. Role of subject compliance. Arch Gen Psychiatry 54:737-742.
6. Kranzler HR, Modesto-Lowe V, Van Kirk J. 2000. Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial. Neuropsy-chopharmacology 22:493-503.
7. Kydonieus AF. 1987. In: Kydonieus AF, Berner B, editors. Transdermal delivery of drugs. Boca Raton, FL: CRC Press.
8. Chen YL, Chun LL, Enscore DJ. 1986. Transdermal therapeutic systems for the administration of naloxone, naltrexone, and nalbuphine. US Patent, # 4,573,995 ed., U.S.A.: Alza.
9. Vigroux A, Bergon M, Zedde C. 1995. Cyclizationactivated prodrugs: N-(substituted 2-hydroxyphenyl and 2-hydroxypropyl)carbamates based on ringopened derivatives of active benzoxazolones and oxazolidinones as mutual prodrugs of acetaminophen. J Med Chem 38:3983-3994.
10. Hussain MA, Aungst BJ, Koval CA, Shefter E. 1988. Improved buccal delivery of opioid analgesics and antagonists with bitterless prodrugs. Pharm Res 5:615-618. (Pubitemid 18259221)
11. Hussain MA, Koval CA, Myers MJ, Shami EG, Shefter E. 1987. Improvement of the oral bioavailability of naltrexone in dogs: A prodrug approach. J Pharm Sci 76:356-358.
12. Vlieghe P, Bihel F, Clerc T, Pannecouque C, Witvrouw M, De Clercq E, Salles JP, Chermann JC, Kraus JL. 2001. New 3′-azido-3′- deoxythymidin-5′- yl O-(omega-hydroxyalkyl) carbonate prodrugs: Synthesis and anti-HIV evaluation. J Med Chem 44:777-786. (Pubitemid 32171674)
13. Pillai O, Hamad MO, Crooks PA, Stinchcomb AL. 2004. Physicochemical evaluation, in vitro human skin diffusion, and concurrent biotransformation of 3-O-alkyl carbonate prodrugs of naltrexone. Pharm Res 21:1146-1152. (Pubitemid 38954198)
14. Stinchcomb AL, Swaan PW, Ekabo O, Harris KK, Browe J, Hammell DC, Cooperman TA, Pearsall M. 2002. Straight-chain naltrexone ester prodrugs: Diffusion and concurrent esterase biotransformation in human skin. J Pharm Sci 91:2571-2578. (Pubitemid 35379414)
15. Alexander J, Fromtling RA, Bland JA, Pelak BA, Gilfillan EC. 1991. (Acyloxy)alkyl carbamate prodrugs of norfloxacin. J Med Chem 34:78-81.
16. Savolainen J, Leppanen J, Forsberg M, Taipale H, Nevalainen T, Huuskonen J, Gynther J, Mannisto PT, Jarvinen T. 2000. Synthesis and in vitro/in vivo evaluation of novel oral N-alkyl- and N,N-dialkylcarbamate esters of entacapone. Life Sci 67:205-216. (Pubitemid 30414487)
17. Sun X, Zeckner DJ, Current WL, Boyer R, McMillian C, Yumibe N, Chen SH. 2001. N-acyloxymethyl carbamate linked prodrugs of pseudomycins are novel antifungal agents. Bioorg Med Chem Lett 11:1875-1879. (Pubitemid 32675308)
18. Alexander J, Cargill R, Michelson SR, Schwam H. 1988. (Acyloxy)alkyl carbamates as novel bioreversible prodrugs for amines: Increased permeation through biological membranes. J Med Chem 31: 318-322. (Pubitemid 18045356)
19. Carvalho E, Francisco AP, Iley J, Rosa E. 2000. Triazene drug metabolites. Part 17. Synthesis and plasma hydrolysis of acyloxymethyl carbamate derivatives of antitumour triazenes. Bioorg Med Chem 8:1719-1725.
20. Fort JJ, Shao ZZ, Mitra AK. 1993. Transport and degradation characteristics of methotrexate dialkyl ester prodrugs across tape-stripped hairless mouse skin. Int J Pharm 100:233-239.
21. Kligman AM, Christophers E. 1963. Preparation of isolated sheets of human stratum corneum. Arch Dermatol 88:702-705.
22. Stinchcomb AL, Dua R, Paliwal A, Woodard RW, Flynn GL. 1995. A solubility and related physicochemical property comparison of buprenorphine and its 3-alkyl esters. Pharm Res 12:1526-1529.
23. Hewitt PG, Perkins J, Hotchkiss SA. 2000. Metabolism of fluroxypyr, fluroxypyr methyl ester, and the herbicide fluroxypyr methylheptyl ester. II. In rat skin homogenates. Drug Metab Dispos 28:755-759. (Pubitemid 30470824)
24. Hewitt PG, Perkins J, Hotchkiss SA. 2000. Metabolism of fluroxypyr, fluroxypyr methyl ester, and the herbicide fluroxypyr methylheptyl ester. I. During percutaneous absorption through fresh rat and human skin in vitro. Drug Metab Dispos 28:748-754. .
25. Magnusson BM, Anissimov YG, Cross SE, Roberts MS. 2004. Molecular size as the main determinant of solute maximum flux across the skin. J Invest Dermatol 122:993-999.
26. Stehle RG, Ho NF, Barsuhn CL, Stefanski KJ. 1989. Local topical delivery of drugs: A model incorporating simultaneous diffusion and metabolic intercon-version between drug and a single metabolite in the skin. J Theor Biol 138:1-15.
27. Yu CD, Fox JL, Ho NF, Higuchi WI. 1979. Physical model evaluation of topical prodrug delivery-simultaneous transport and bioconversion of vidarabine- 5′-valerate II: Parameter determinations. J Pharm Sci 68:1347-1357. (Pubitemid 10210461)
28. Yu CD, Fox JL, Ho NF, Higuchi WI. 1979. Physical model evaluation of topical prodrug delivery-simultaneous transport and bioconversion of vidarabine-5′-valerate I: Physical model development. J Pharm Sci 68:1341-1346. (Pubitemid 10210460)
29. Guzek DB, Kennedy AH, McNeill SC, Wakshull E, Potts RO. 1989. Transdermal drug transport and metabolism. I. Comparison of in vitro and in vivo results. Pharm Res 6:33-39.
30. Potts RO, McNeill SC, Desbonnet CR, Wakshull E. 1989. Transdermal drug transport and metabolism. II. The role of competing kinetic events. Pharm Res 6:119-124.
31. Fox JL, Cheng-Dur Y, Higuchi WI, Ho NFH. 1979. General physical model for simultaneous diffusion and metabolism in biological membranes. The computational approach for the steady-state case. Int J Pharm 2:41-57.
32. Bando H, Mohri S, Yamashita F, Takakura Y, Hashida M. 1997. Effects of skin metabolism on percutaneous penetration of lipophilic drugs. J Pharm Sci 86:759-761. (Pubitemid 27248830)
33. Hammell DC, Hamad M, Vaddi HK, Crooks PA, Stinchcomb AL. 2004. A duplex "Gemini" prodrug of naltrexone for transdermal delivery. J Control Release 97:283-290. (Pubitemid 38759485)
34. Hansen KT, Jansen JA, Mengel H, Christensen JV, Bundgaard H. 1992. Enhanced bioavailability of a new class of dopamine D-1 antagonists following oral administration of their carbamic acid ester prodrugs to dogs. Int J Pharm 79:205-212.
35. Olsson OAT, Svensson LA. 1984. New lipophilic terbutaline ester prodrugs with long effect duration. Pharm Res 1:19-23.
36. Thorberg SO, Berg S, Lundstrom J, Pettersson B, Wijkstrom A, Sanchez D, Lindberg P, Nilsson JL. 1987. Carbamate ester derivatives as potential prodrugs of the presynaptic dopamine autoreceptor agonist (-)-3-(3-hydroxyphenyl)-N- propylpiperidine. J Med Chem 30:2008-2012. (Pubitemid 18046056)
37. Safadi M, Oliyai R, Stella VJ. 1993. Phosphoryloxymethyl carbamates and carbonates-Novel water-soluble prodrugs for amines and hindered alcohols. Pharm Res 10:1350-1355. (Pubitemid 23261839)
38. Bar-On P, Millard CB, Harel M, Dvir H, Enz A, Sussman JL, Silman I. 2002. Kinetic and structural studies on the interaction of cholinesterases with the anti-Alzheimer drug rivastigmine. Biochemistry 41:3555-3564. (Pubitemid 34224667)
39. Bartolucci C, Siotto M, Ghidini E, Amari G, Bolzoni PT, Racchi M, Villetti G, Delcanale M, Lamba D. 2006. Structural determinants of Torpedo californica acetylcholinesterase inhibition by the novel and orally active carbamate based anti-alzheimer drug ganstigmine (CHF-2819). J Med Chem 49: 5051-5058. (Pubitemid 44260202)
40. Groner E, Ashani Y, Schorer-Apelbaum D, Sterling J, Herzig Y, Weinstock M. 2007. The kinetics of inhibition of human acetylcholinesterase and butyrylcholinesterase by two series of novel carbamates. Mol Pharmacol 71:1610-1617. (Pubitemid 47010914)
41. Bolognesi ML, Bartolini M, Cavalli A, Andrisano V, Rosini M, Minarini A, Melchiorre C. 2004. Design, synthesis, and biological evaluation of conformationally restricted rivastigmine analogues. J Med Chem 47:5945-5952. (Pubitemid 39507336)
42. Sterling J, Herzig Y, Goren T, Finkelstein N, Lerner D, Goldenberg W, Miskolczi I, Molnar S, Rantal F, Tamas T, Toth G, Zagyva A, Zekany A, Finberg J, Lavian G, Gross A, Friedman R, Razin M, Huang W, Krais B, Chorev M, Youdim MB, Weinstock M. 2002. Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease. J Med Chem 45:5260-5279. (Pubitemid 35429165)
43. Kiptoo PK. 2007. Transdermal delivery of naltrexone and its active metabolite, 6-beta-naltrexol, via novel tripartate codrugs linked to bupropion and hydroxybupropion. PhD Thesis, Department of Pharmaceutical Sciences, University of Kentucky College of Pharmacy, University of Kentucky, p. 199.
44. Hamad MO, Kiptoo PK, Stinchcomb AL, Crooks PA. 2006. Synthesis and hydrolytic behavior of two novel tripartate codrugs of naltrexone and 6beta-naltrexol with hydroxybupropion as potential alcohol abuse and smoking cessation agents. Bioorg Med Chem 14:7051-7061.
45. Kiptoo PK, Hamad MO, Crooks PA, Stinchcomb AL. 2006. Enhancement of transdermal delivery of 6-beta-naltrexol via a codrug linked to hydroxybupropion. J Control Release 113:137-145.
46. Kiptoo PK, Paudel KS, Hammell DC, Hamad MO, Crooks PA, Stinchcomb AL. 2008. In vivo evaluation of a transdermal codrug of 6-beta-naltrexol linked to hydroxybupropion in hairless guinea pigs. Eur J Pharm Sci 33:371-379.
47. Potts RO, Guy RH. 1992. Predicting skin permeability. Pharm Res 9:663-669.
48. Potts RO, Guy RH. 1995. A predictive algorithm for skin permeability: The effects of molecular size and hydrogen bond activity. Pharm Res 12:1628-1633.
49. Pugh WJ, Roberts MS, Hadgraft J. 1996. Epidermal permeability-penetrant structure relationship: 3. the effect of hydrogen bonding interactions and molecular size on diffusion across the stratum corneum. Int J Pharm 138:149-165. (Pubitemid 26281172)
50. Roberts MS, Pugh WJ, Hadgraft J, Watkinson AC. 1995. Epidermal permeability-penetrant structure relationships. 1. An analysis of methods of predicting penetration of monofunctional solutes from aqueous solutions. Int J Pharm 126:219-233. (Pubitemid 26015638)
51. Roberts WJ, Sloan KB. 2000. Prediction of transdermal flux of prodrugs of 5-fluorouracil, theophylline, and 6-mercaptopurine with a series/parallel model. J Pharm Sci 89:1415-1431.
52. Xiang TX, Anderson BD. 1995. Phospholipid surface density determines the partitioning and permeability of acetic acid in DMPC:cholesterol bilayers. J Membr Biol 148:157-167.
53. Xiang TX, Anderson BD. 1997. Permeability of acetic acid across gel and liquid-crystalline lipid bilayers conforms to free-surface-area theory. Biophys J 72:223-237.
54. Xiang TX, Anderson BD. 1994. Substituent contributions to the transport of substituted p-toluic acids across lipid bilayer membranes. J Pharm Sci 83: 1511-1518.
55. Walter A, Gutknecht J. 1986. Permeability of small nonelectrolytes through lipid bilayer membranes. J Membr Biol 90:207-217. (Pubitemid 16075232)
56. Xiang TX, Anderson BD. 1998. Influence of chain ordering on the selectivity of dipalmitoylphosphatidylcholine bilayer membranes for permeant size and shape. Biophys J 75:2658-2671.
57. Xiang TX, Anderson BD. 1994. The relationship between permeant size and permeability in lipid bilayer membranes. J Membr Biol 140:111-122.
58. Xiang TX, Anderson BD. 1994. Molecular distributions in interphases: Statistical mechanical theory combined with molecular dynamics simulation of a model lipid bilayer. Biophys J 66:561-572. (Pubitemid 2056048)
59. Bemporad D, Luttmann C, Essex JW. 2004. Computer simulation of small molecule permeation across a lipid bilayer: Dependence on bilayer properties and solute volume, size, and cross-sectional area. Biophys J 87:1-13. (Pubitemid 38880059)
60. Mitragotri S. 2002. A theoretical analysis of permeation of small hydrophobic solutes across the stratum corneum based on Scaled Particle Theory. J Pharm Sci 91:744-752. (Pubitemid 34639637)
61. Gerebtzoff G, Seelig A. 2006. In silico prediction of blood-brain barrier permeation using the calculated molecular cross-sectional area as main parameter. J Chem Inf Model 46:2638-2650.
62. Seelig A. 2007. The role of size and charge for bloodbrain barrier permeation of drugs and fatty acids. J Mol Neurosci 33:32-41. (Pubitemid 47574956)